A Phase 1 interventional study of Zavegepant and Placebo in Asthma, sponsored by Pfizer. Terminated at 10 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-19.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.
Among the 24 studies in Asthma by Pfizer, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2021, is one of 8 in phase 1, and was the 20th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
Pfizer · Sites in United States, Japan
Ages 12–80
Pfizer · Sites in United States, Belgium
Ages 18–65 · Healthy volunteers
Pfizer · Sites in United States, Argentina, Belgium and 12 more countries
Ages 18–75
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 48 across the 20 interventional studies, 20 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Asthma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT07660731PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Asthma by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.
Exclusion Criteria:
-
Zavegepant 150 mg BID
Drug: Zavegepant
Matching placebo 150 mg BID
Drug: Placebo
150 mg BID
Also known as: BHV3500
Placebo matching active drug
Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge
Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 3 and 7 on Day 27 divided by the baseline value from Day 27. Analysis was performed using analysis of covariance (ANCOVA) model with treatment as main effect and baseline FEV1 as covariate.
Time frame: Baseline (pre-allergen challenge on Day 27) and anytime between 3 and 7 hours post-challenge on Day 27
Maximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge
Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 0 to 2 hours post allergen challenge to assess early asthmatic response (EAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 0 and 2 on Day 27 divided by the baseline value from Day 27. Analysis was performed using ANCOVA model with treatment as main effect and baseline FEV1 as covariate.
Time frame: Baseline (pre-allergen challenge on Day 27) and anytime between 0 and 2 hours post-challenge on Day 27
Change in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge
Airway hyperresponsiveness was assessed using methacholine provocation concentration causing a 20% decline in FEV1 (PC20). Change in PC20 from pre-allergen to post-allergen = PC20 in post-allergen challenge minus PC20 in pre-allergen challenge. Shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day 28 minus Day 26), and baseline shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day -13 minus Day-15). Analysis was performed using ANCOVA model with treatment as main effect and baseline shift as covariate.
Time frame: From Day -15 to Day 28
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any adverse event that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or other important medical events. TEAEs were events with onset dates on or after the start of the study drug.
Time frame: From start of treatment on Day 1 up to Day 41
Number of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment
The following laboratory parameters were assessed: hematology (eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets), chemistry (Albumin, alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, glucose, low-density lipoproteins \[LDL\], lactate dehydrogenase, potassium, sodium, triglycerides) and urinalysis (urine glucose and urine protein). Clinically significant laboratory test abnormalities were Grade 3 (severe) to Grade 4 (potentially life-threatening) laboratory test results graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 except for glucose, LDL cholesterol, uric acid and urinalysis which were graded using Division of Aids (DAIDS) Version 2.1 where, Grade 3=severe and Grade 4=potentially life-threatening. Number of participants with clinically significant abnormalities in any laboratory parameter is presented.
Time frame: From start of treatment on Day 1 to Day 28
| Milestone | Zavegepant | Placebo |
|---|---|---|
| Started | 7 | 8 |
| Completed | 7 | 6 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 3 and 7 on Day 27 divided by the baseline value from Day 27. Analysis was performed using analysis of covariance (ANCOVA) model with treatment as main effect and baseline FEV1 as covariate.
| Percent change | Zavegepant | Placebo |
|---|---|---|
| Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge | 19.7 (9.9 to 29.5) | 29.5 (18.8 to 40.1) |
Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 0 to 2 hours post allergen challenge to assess early asthmatic response (EAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 0 and 2 on Day 27 divided by the baseline value from Day 27. Analysis was performed using ANCOVA model with treatment as main effect and baseline FEV1 as covariate.
| Percent change | Zavegepant | Placebo |
|---|---|---|
| Maximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge | 30.5 (20.1 to 40.8) | 34.4 (23.2 to 45.5) |
Airway hyperresponsiveness was assessed using methacholine provocation concentration causing a 20% decline in FEV1 (PC20). Change in PC20 from pre-allergen to post-allergen = PC20 in post-allergen challenge minus PC20 in pre-allergen challenge. Shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day 28 minus Day 26), and baseline shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day -13 minus Day-15). Analysis was performed using ANCOVA model with treatment as main effect and baseline shift as covariate.
| Milligrams per milliliter | Zavegepant | Placebo |
|---|---|---|
| Change in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge | 0.165 (-0.192 to 0.521) | -0.259 (-0.671 to 0.154) |
An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any adverse event that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or other important medical events. TEAEs were events with onset dates on or after the start of the study drug.
| Participants | Zavegepant | Placebo |
|---|---|---|
| TEAEs | 3 | 4 |
| TESAEs | 0 | 0 |
The following laboratory parameters were assessed: hematology (eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets), chemistry (Albumin, alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, glucose, low-density lipoproteins \[LDL\], lactate dehydrogenase, potassium, sodium, triglycerides) and urinalysis (urine glucose and urine protein). Clinically significant laboratory test abnormalities were Grade 3 (severe) to Grade 4 (potentially life-threatening) laboratory test results graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 except for glucose, LDL cholesterol, uric acid and urinalysis which were graded using Division of Aids (DAIDS) Version 2.1 where, Grade 3=severe and Grade 4=potentially life-threatening. Number of participants with clinically significant abnormalities in any laboratory parameter is presented.
| Participants | Zavegepant | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment | 0 | 0 |
Collected over On treatment: From start of study treatment on Day 1 up to Day 28 and Follow up: From Day 29 to Day 41. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant (On Treatment) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Placebo (On Treatment) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Zavegepant (Follow-up) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Placebo (Follow-up) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Zavegepant (On Treatment) | Placebo (On Treatment) | Zavegepant (Follow-up) | Placebo (Follow-up) |
|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 2/7 | 0/8 | 0/7 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 1/7 | 1/8 | 0/7 | 0/8 |
| PyrexiaGeneral disorders | 1/7 | 1/8 | 0/7 | 0/8 |
| FatigueGeneral disorders | 1/7 | 0/8 | 0/7 | 0/8 |
| HeadacheNervous system disorders | 1/7 | 1/8 | 0/7 | 0/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/7 | 1/8 | 0/7 | 0/8 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/8 |
| Paranasal sinus discomfortRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/8 |
| Pulmonary congestionRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/8 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/8 |
Safety analysis set included all randomized participants who received at least 1 dose of study therapy.
| Age, Continuous(Years) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Mean | 36.7 ± 14.40 | 29.3 ± 11.06 | 32.7 ± 12.84 |
| Sex: Female, Male(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 1 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 5 | 10 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2021 to primary completion in Mar 2023, 17 months.
Results were first posted in Jul 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant